Price History
Feb 9, 2026 — Aug 25, 2026Investment Snapshot
- Trading 364% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- Strong ROE of 29.1% with 18.8% net margin
ILLUMINA, INC. (ILMN) is a Healthcare company operating in Laboratory Analytical Instruments, listed on the NASDAQ , with a market capitalisation of $33.7 billion . Key value metrics: P/E ratio 40.9, P/B ratio 11.88, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
ILLUMINA, INC. — Fundamental Analysis Summary
ILLUMINA, INC. (ILMN) is currently trading 364% above its Graham Number of $48.07, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 40.9x.
On financial health, ILMN shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and strong return on equity of 29.1% (sector average: -20.1%), and minimal leverage with a debt-to-equity ratio of 0.00.
StockPik's composite Value Score for ILMN is 67/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ILMN reports a high gross margin of 66.4% (sector average: 37.4%) and a strong operating margin of 20.4%.
ILMN shows revenue declining at 1% year-over-year, with earnings growing at 170%.